Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns

January 4, 2018

Spark Therapeutics priced Luxturna, a gene therapy for a rare form of blindness, at $850,000.   The first gene therapy in the U.S., approved last month to treat a rare, inherited form of blindness, now has a price tag: $850,000.   That makes the treatment, called Luxturna and made by Spark Therapeutics, the most expensive […]

The California Co-Pay Conundrum

January 2, 2018

TrialCard Addresses AB 265 On October 9, 2017, California Governor Jerry Brown signed AB 265 into law. This landmark piece of legislation modified the California Health and Safety Code to prohibit the “offering” of any discount, product voucher, or other out-of-pocket cost reduction tool by drug manufacturers when there is an FDA-approved therapeutic equivalent. As […]

Gilead Launches Hep C Drug Sovaldi in China at One-Fifth of U.S. Price

November 30, 2017

Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it will cost 58,980 yuan ($8,937) in the region, just one-fifth of its price tag in the US – a price which has fallen rapidly from the $84,000 it originally launched at.   There are around […]

2018 Healthcare Predictions

November 29, 2017

Every year, InCrowd surveys physicians across a wide range of specialties to better understand their perspective on healthcare policies and trends, and learn what they think will happen in the year ahead. Join us as we take a look at physician predictions and insights for 2018, and how they compare to years past. In the […]

Surescripts Joins Epic, CVS to Deliver Drug Pricing Info in EHRs

November 9, 2017

Surescripts announced an effort to increase transparency around prescription drug benefits and pricing. Working with EHR vendors and pharmacy benefit managers, Surescripts will provide real-time patient-specific benefit and price information to providers at the point of care. Once integrated with the EHR, patients and doctors will also be able to see information and pricing on […]

RxTE Health Promotes David Henka to Chief Executive Officer

November 8, 2017

Pharmacy Benefit Solution Provider Announces Company President Will Also Assume Role of CEO Silicon Valley, CA- November 7, 2017- RxTE Health (RxTE), a company specializing in pharmacy cost reduction programs for employers, today announced that its president, David Henka, has been promoted to Chief Executive Officer. As CEO, Henka will be responsible for driving the […]

Sharing Negotiated Discounts Could Save Patients More than $800 Annually and Would Increase Premiums About 1 Percent

October 13, 2017

WASHINGTON, Oct. 12, 2017 /PRNewswire-USNewswire/ — Providing access to discounted medicine prices at the point of sale could save certain commercially insured patients with high deductibles and coinsurance $145 to more than $800 annually, according to a new analysis from Milliman that was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). The data […]

Legal Fight Looms Over California’s New Drug Pricing Law

October 12, 2017

California passed a law requiring pharmaceutical companies to explain their price increases, escalating the state-by-state battle between lawmakers trying to bring more transparency to the industry’s practices and drugmakers that oppose the efforts.   The California measure, signed Monday by Governor Jerry Brown, is among the most aggressive state efforts to peel back the secretive […]

Absent Federal Action, States Take The Lead On Curbing Drug Costs

October 5, 2017

Lawmakers in Maryland are daring to legislate where their federal counterparts have not: As of Oct. 1, the state will be able to say “no” to some pharmaceutical price spikes.   A new law, which focuses on generic and off-patent drugs, empowers the state’s attorney general to step in if a drug’s price climbs 50 […]

Abbvie’s Hep C Drug Pricing Threatens Gilead’s Dominance

August 10, 2017

Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial. But even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors. AbbVie Inc. last week threw another big […]